Cancers, Vol. 15, Pages 4276: Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Conclusions: In Taiwanese patients with type 2 diabetes mellitus, TZD use is associated with a borderline lower risk of MM, which is more remarkable in patients aged ≥ 65 years. Because of the low incidence of MM, the use of TZD for the prevention of MM may not be cost-effective. Patients who have been treated with TZD may have a survival advantage. Future research is required to confirm the findings.
Source: Cancers - Category: Cancer & Oncology Authors: Chin-Hsiao Tseng Tags: Article Source Type: research
More News: Actos | Avandia | Cancer | Cancer & Oncology | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Health Insurance | Insurance | Myeloma | Statistics | Study | Taiwan Health